LSNE Completes Successful FDA PAI for Sterile Drug Product
News Jun 12, 2015
Lyophilization Services of New England, Inc. (LSNE) has announced that they have completed a successful Pre-Approval Inspection (PAI) and General GMP Inspection in April 2015. This inspection clears the way for the 25 Commerce Drive manufacturing site, located in Bedford, NH, to manufacture commercial drug product for US distribution.
The inspection concluded with a recommendation for approval and the Establishment Inspection Report (EIR) has been received. This is the second PAI at the Commerce Drive facility, the first inspection was for a bulk drug intermediate lyophilized in LSNE’s 260 square foot lyophilizer.
Shawn Cain, Chief Operating Officer of LSNE stated, “The completion of this inspection is a critical milestone for LSNE as it is the first PAI for a sterile product at the 25 Commerce Road facility. This is also our second site to now be successfully inspected by the FDA to produce commercial products in the past few months. This demonstrates LSNE’s commitment to meeting all applicable regulatory standards for the production of commercial medical devices, bulk intermediates and sterile injectable drugs. It is only through the talent and dedication of our staff that we have been able to achieve and maintain this level of compliance.”
LSNE has also added additional capabilities across their three sites and they plan to continue expanding in the coming year(s). The 2015 master plan includes expansion of QC analytical testing capabilities, ICH stability chambers, additional complex formulation capabilities, as well as adding increased manufacturing capacity.
LSNE continues its path towards becoming the premier turn-key CMO for its clinical and commercial clients and its commitment to reduce the time and cost of bringing client projects from bench to market.
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Medherant Expands Team with Appointment of David Davies as Head of DevelopmentNews
Medherant Ltd, a leader in next-generation transdermal drug delivery, is pleased to announce the appointment of a new senior executive, David Davies, as Head of Development.READ MORE
Empowering Women in Technology Key to Boosting UK EconomyNews
A new report launched at London Stock Exchange for International Women’s Day, reveals the critical role women play in driving economic growth across the UK, with detailed research on 1,279 women-led companies showing a total contribution of £25.9 billion in revenue to the UK economy.READ MORE
Comments | 0 ADD COMMENT
World Congress on Clinical And Medical Microbiology
Sep 10 - Sep 11, 2018